BioAtla (NASDAQ: BCAB)
$0.49
(-4.4%)
-$0.02
Price as of June 10, 2025, 4:00 p.m. ET
BioAtla Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BioAtla Company Info
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.